Il2 (interleukin 2) - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Il2 (interleukin 2) Rattus norvegicus
Analyze
Symbol: Il2
Name: interleukin 2
RGD ID: 620047
Description: Enables carbohydrate binding activity; glycosphingolipid binding activity; and signaling receptor binding activity. Involved in several processes, including positive regulation of T cell activation; protein kinase C-activating G protein-coupled receptor signaling pathway; and regulation of protein phosphorylation. Located in extracellular space. Used to study cystitis. Biomarker of allergic rhinitis; colorectal carcinoma; and tongue squamous cell carcinoma. Human ortholog(s) of this gene implicated in several diseases, including Takayasu's arteritis; auditory system disease (multiple); autoimmune disease (multiple); carcinoma (multiple); and neurodegenerative disease (multiple). Orthologous to human IL2 (interleukin 2); PARTICIPATES IN interleukin-12 signaling pathway; interleukin-2 signaling pathway; interleukin-23 signaling pathway; INTERACTS WITH (+)-pilocarpine; (R)-lipoic acid; 1,2-dichloroethane.
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: IL-2; interleukin-2; T-cell growth factor; TCGF
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.22120,004,862 - 120,009,566 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl2120,004,862 - 120,009,566 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx2126,574,220 - 126,578,924 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.02124,686,729 - 124,691,433 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.02119,315,685 - 119,320,389 (-)NCBIRnor_WKY
Rnor_6.02123,847,150 - 123,851,854 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl2123,847,150 - 123,851,854 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.02143,460,866 - 143,465,570 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.42123,655,005 - 123,659,709 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.12123,599,966 - 123,604,671 (-)NCBI
Celera2114,959,889 - 114,964,593 (-)NCBICelera
Cytogenetic Map2q25NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


Disease Annotations     Click to see Annotation Detail View
acquired immunodeficiency syndrome  (ISO)
Acute Lung Injury  (IEP)
adult T-cell leukemia/lymphoma  (ISO)
aggressive periodontitis  (ISO)
allergic contact dermatitis  (ISO)
allergic disease  (ISO)
allergic rhinitis  (IEP)
alopecia areata  (ISO)
Alzheimer's disease  (ISO)
Amebic Liver Abscess  (ISO)
amnestic disorder  (ISO)
anemia  (ISO)
anogenital venereal wart  (ISO)
Anorexia  (ISO)
Asthenia  (ISO)
asthma  (ISO)
ataxia telangiectasia  (ISO)
atherosclerosis  (ISO)
atopic dermatitis  (ISO)
atrial fibrillation  (ISO)
autistic disorder  (ISO)
autoimmune hepatitis  (ISO)
autoimmune thrombocytopenic purpura  (ISO)
bacterial infectious disease  (ISO)
Behcet's disease  (ISO)
birdshot chorioretinopathy  (ISO)
Brain Injuries  (ISO)
Brain Neoplasms  (ISO)
bullous pemphigoid  (ISO)
Carcinoma, Lewis Lung  (ISO)
cholestasis  (ISO)
cholesteatoma of middle ear  (ISO)
Choroidal Neovascularization  (ISO)
Chronic Hepatitis B  (ISO)
Chronic Hepatitis C  (ISO)
colorectal carcinoma  (IEP)
Coronavirus infectious disease  (ISO)
COVID-19  (ISO)
cystitis  (IDA)
disease of cellular proliferation  (ISO)
drug allergy  (ISO)
Drug Eruptions  (ISO)
Entamoebiasis  (ISO)
Experimental Arthritis  (IDA,IEP)
Experimental Autoimmune Uveoretinitis  (IEP,ISO)
Experimental Colitis  (IEP)
Experimental Diabetes Mellitus  (IEP)
Experimental Liver Cirrhosis  (IEP)
Experimental Melanoma  (ISO)
Experimental Neoplasms  (ISO)
Femoral Fractures  (IEP)
Fever  (ISO)
glioblastoma  (ISO)
glomerulonephritis  (ISO)
Graft vs Host Disease  (ISO)
Graves ophthalmopathy  (ISO)
Graves' disease  (ISO)
head and neck squamous cell carcinoma  (ISO)
hepatitis B  (ISO)
hepatitis C  (ISO)
hepatocellular carcinoma  (ISO)
herpes zoster  (ISO)
high grade glioma  (ISO)
human immunodeficiency virus infectious disease  (ISO)
Human Influenza  (ISO)
Hyperalgesia  (IDA,IEP,IMP)
Hyperkinesis  (ISO)
Hypotension  (ISO)
inflammatory bowel disease  (ISS)
interstitial lung disease  (ISO)
juvenile rheumatoid arthritis  (ISO)
Kidney Neoplasms  (ISO)
Knee Osteoarthritis  (ISO)
leishmaniasis  (ISO)
leukemia  (ISO)
leukopenia  (ISO)
limited scleroderma  (ISO)
liver cirrhosis  (ISO)
Liver Metastasis  (ISO)
Liver Neoplasms  (ISO)
lung disease  (ISO)
Lung Neoplasms  (ISO)
major depressive disorder  (ISO)
melanoma  (ISO)
Multi-Infarct Dementia  (ISO)
Neoplasm Metastasis  (ISO)
Neoplasm, Residual  (ISO)
nephrotic syndrome  (ISO)
Neurodevelopmental Disorders  (ISO)
Neurogenic Inflammation  (IEP)
open-angle glaucoma  (ISO)
Oral Lichen Planus  (ISO)
oral squamous cell carcinoma  (ISO)
otitis media  (ISO)
Pain  (ISO)
pancreatic cancer  (ISO)
pemphigus  (ISO)
Perennial Allergic Rhinitis  (ISO)
post-traumatic stress disorder  (ISO)
primary immunodeficiency disease  (ISO)
Prostatic Neoplasms  (ISO)
psoriasis  (ISO)
renal cell carcinoma  (ISO)
rheumatoid arthritis  (ISO)
rhinitis  (ISO)
sensorineural hearing loss  (ISO)
severe combined immunodeficiency  (ISO)
sinusitis  (ISO)
Sjogren's syndrome  (ISS)
squamous cell carcinoma  (ISO)
Staphylococcal Infections  (ISO)
systemic lupus erythematosus  (ISO)
systemic scleroderma  (ISO)
Takayasu's arteritis  (ISO)
tongue squamous cell carcinoma  (IEP)
Transplant Rejection  (IMP,ISO)
type 1 diabetes mellitus  (ISO)
urinary bladder cancer  (ISO)
uveitis  (ISO)
Vaginal Neoplasms  (ISO)
viral hepatitis  (ISO)
vitiligo  (ISO)
Zellweger syndrome  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-catechin  (ISO)
(+)-pilocarpine  (EXP)
(-)-epigallocatechin 3-gallate  (ISO)
(R)-lipoic acid  (EXP)
(S)-colchicine  (ISO)
(S)-nicotine  (ISO)
1,2-dichloroethane  (EXP)
1,2-dimethylhydrazine  (EXP)
1,3-benzothiazole-2-thiol  (ISO)
1,4-phenylenediamine  (ISO)
1-chloro-2,4-dinitrobenzene  (ISO)
1-fluoro-2,4-dinitrobenzene  (ISO)
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (ISO)
1-naphthaleneacetic acid  (ISO)
15-acetyldeoxynivalenol  (ISO)
17alpha-ethynylestradiol  (ISO)
17beta-estradiol  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,2',5,5'-tetrachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4,6-trinitrobenzenesulfonic acid  (ISO)
2,4-D  (ISO)
2,6-di-tert-butyl-4-methylphenol  (ISO)
2-amino-2-deoxy-D-glucopyranose  (ISO)
2-arachidonoylglycerol  (ISO)
2-ethylhexan-1-ol  (ISO)
2-tert-butylhydroquinone  (ISO)
3'-O-(4-Benzoyl)benzoyl ATP  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3,3'-diindolylmethane  (ISO)
3-acetyldeoxynivalenol  (ISO)
3-isobutyl-1-methyl-7H-xanthine  (ISO)
4'-epidoxorubicin  (ISO)
4'-hydroxydiclofenac  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-(ethoxymethylene)-2-phenyloxazol-5-one  (ISO)
4-aminobenzoic acid  (ISO)
4-hydroxynon-2-enal  (ISO)
4-nitroaniline  (ISO)
4-tolyl isocyanate  (ISO)
5'-S-methyl-5'-thioadenosine  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (ISO)
7,12-dimethyltetraphene  (ISO)
7,8-dihydroxycoumarin  (EXP)
9-cis-retinoic acid  (ISO)
acetylsalicylic acid  (ISO)
acrolein  (ISO)
actinomycin D  (ISO)
adenosine  (ISO)
alclometasone dipropionate  (ISO)
aldehydo-D-glucosamine  (ISO)
aldicarb  (ISO)
all-trans-retinoic acid  (EXP,ISO)
all-trans-retinol  (ISO)
alpha-hexylcinnamaldehyde  (ISO)
alprazolam  (ISO)
aluminium hydroxide  (ISO)
ammonium chloride  (EXP)
Ammothamnine  (EXP)
amphotericin B  (ISO)
anethole  (ISO)
anthracen-2-amine  (ISO)
arjunolic acid  (EXP)
arotinoid acid  (ISO)
arsane  (ISO)
arsenic atom  (ISO)
arsenic trichloride  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
bathocuproine disulfonic acid  (ISO)
benzamide  (EXP)
benzene  (EXP,ISO)
benzethonium chloride  (ISO)
benzo[a]pyrene  (EXP,ISO)
benzocaine  (ISO)
berberine  (ISO)
beryllium sulfate  (ISO)
beta-D-glucosamine  (ISO)
beta-endorphin  (ISO)
betamethasone valerate  (ISO)
betulin  (ISO)
bifenthrin  (ISO)
bisphenol A  (EXP,ISO)
bleomycin A2  (EXP)
boric acid  (EXP)
boron atom  (EXP)
bromodichloromethane  (ISO)
buprenorphine  (ISO)
butan-1-ol  (ISO)
butane-2,3-dione  (ISO)
C60 fullerene  (ISO)
cadmium dichloride  (EXP,ISO)
Calcimycin  (ISO)
calcitriol  (EXP,ISO)
cannabidiol  (ISO)
Cannabinol  (ISO)
capsaicin  (EXP,ISO)
capsazepine  (ISO)
carbamazepine  (EXP)
carbaryl  (ISO)
carbofuran  (ISO)
carbon nanotube  (ISO)
celecoxib  (EXP)
cerium trichloride  (ISO)
chloromethylisothiazolinone  (ISO)
chloroquine  (ISO)
chlorpromazine  (ISO)
choline  (ISO)
chromium(6+)  (ISO)
ciglitazone  (ISO)
ciprofloxacin  (EXP)
cis-caffeic acid  (ISO)
cisplatin  (ISO)
citral  (ISO)
clonidine  (EXP)
clonidine (amino form)  (EXP)
clonidine (imino form)  (EXP)
cobalt atom  (ISO)
cobalt dichloride  (ISO)
cocaine  (ISO)
coformycin  (ISO)
copper(II) nitrate  (ISO)
cortisol  (ISO)
coumestrol  (ISO)
crotonaldehyde  (ISO)
curcumin  (ISO)
cyclophosphamide  (EXP,ISO)
cyclosporin A  (EXP,ISO)
dapsone  (ISO)
DDT  (ISO)
decabromodiphenyl ether  (EXP,ISO)
deoxynivalenol  (ISO)
dexamethasone  (ISO)
dextran sulfate  (ISO)
diarsenic trioxide  (ISO)
diazinon  (ISO)
Dibenzo[a,i]pyrene  (ISO)
dibutyl phthalate  (ISO)
dichloroacetic acid  (ISO)
dichlorvos  (ISO)
diclofenac  (ISO)
dieldrin  (ISO)
diethanolamine  (ISO)
digoxin  (ISO)
diiodine  (EXP)
diisopropyl fluorophosphate  (ISO)
Dimaprit  (ISO)
dimethyl sulfoxide  (ISO)
dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium  (ISO)
diphenylmethane-4,4'-diisocyanate  (ISO)
dipyridamole  (ISO)
doxorubicin  (EXP,ISO)
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor  (ISO)
elemental boron  (EXP)
elemental selenium  (EXP)
endosulfan  (ISO)
erlotinib hydrochloride  (ISO)
ethanol  (ISO)
eugenol  (ISO)
famotidine  (ISO)
fenitrothion  (EXP,ISO)
fentanyl  (ISO)
ferric oxide  (ISO)
fluticasone  (ISO)
folic acid  (ISO)
formaldehyde  (EXP,ISO)
fragrance  (ISO)
fructose  (EXP)
fumigaclavine C  (ISO)
fumonisin B1  (ISO)
gamma-linolenic acid  (ISO)
Gastrodin  (ISO)
genistein  (EXP)
geranial  (ISO)
Glutathione ethyl ester  (ISO)
Goe 6976  (ISO)
graphite  (ISO)
heroin  (ISO)
hexachlorobenzene  (EXP)
histamine  (ISO)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
imidurea  (ISO)
imiquimod  (ISO)
indirubin-3'-monoxime  (ISO)
indole-3-acetic acid  (ISO)
indole-3-methanol  (ISO)
indometacin  (ISO)
ionomycin  (EXP,ISO)
irinotecan  (EXP)
isoeugenol  (ISO)
isoniazide  (ISO)
isophorone diisocyanate  (ISO)
isoprenaline  (EXP)
isotretinoin  (EXP)
KN-93  (ISO)
lactacystin  (ISO)
lead diacetate  (ISO)
lead nitrate  (ISO)
lead(II) chloride  (ISO)
lenalidomide  (ISO)
levamisole  (ISO)
linoleic acid  (ISO)
lipoic acid  (EXP)
lipopolysaccharide  (EXP,ISO)
lithium atom  (ISO)
lithium carbonate  (ISO)
lithium chloride  (ISO)
lithium hydride  (ISO)
loperamide  (ISO)
LY294002  (ISO)
lycopene  (ISO)
magnesium dihydroxide  (ISO)
malathion  (ISO)
malonaldehyde  (ISO)
mancozeb  (ISO)
manganese atom  (ISO)
manganese(0)  (ISO)
MC1568  (ISO)
medroxyprogesterone acetate  (ISO)
melatonin  (ISO)
mercury atom  (EXP)
mercury dichloride  (EXP,ISO)
mercury(0)  (EXP)
mesalamine  (ISO)
methadone  (ISO)
methanol  (ISO)
methiocarb  (ISO)
methotrexate  (ISO)
methoxychlor  (EXP)
methyl isocyanate  (ISO)
methylmercury chloride  (ISO)
mevinphos  (ISO)
microcystin-LR  (EXP,ISO)
mifepristone  (ISO)
minocycline  (ISO)
mitogen  (EXP,ISO)
mitomycin C  (ISO)
monocrotophos  (ISO)
Monocyte locomotion inhibitory factor  (ISO)
monodansylcadaverine  (ISO)
monosodium L-glutamate  (EXP)
morphine  (ISO)
mycophenolic acid  (EXP,ISO)
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine  (ISO)
N,N-bis(2-hydroxypropyl)nitrosamine  (EXP)
N,N-diethyl-m-toluamide  (ISO)
N-acetyl-L-cysteine  (EXP,ISO)
N-butyl-N-(4-hydroxybutyl)nitrosamine  (EXP)
N-methyl-N-nitrosourea  (EXP,ISO)
N-nitrosodiethylamine  (EXP)
naloxone  (ISO)
naproxen  (EXP)
naringin  (ISO)
neocuproine  (ISO)
nickel atom  (ISO)
nickel dichloride  (ISO)
nickel sulfate  (ISO)
nicotinamide  (ISO)
nicotine  (ISO)
nilotinib  (EXP)
nitrofurazone  (ISO)
Nivalenol  (ISO)
nonanoic acid  (ISO)
notoginsenoside R1  (ISO)
o-anisidine  (ISO)
ochratoxin A  (ISO)
oridonin  (EXP)
oxidopamine  (ISO)
ozone  (ISO)
p-menthan-3-ol  (ISO)
Paeonol  (ISO)
paracetamol  (ISO)
paraoxon  (ISO)
paraquat  (EXP,ISO)
PCB138  (ISO)
PD 0325901  (ISO)
pentamidine  (ISO)
perfluorononanoic acid  (EXP)
perfluorooctane-1-sulfonic acid  (ISO)
permethrin  (EXP)
phenanthridone  (EXP)
phenethyl caffeate  (ISO)
phenyl benzoate  (ISO)
PhIP  (ISO)
phorbol 13-acetate 12-myristate  (EXP,ISO)
phthalic anhydride  (ISO)
piperazine  (ISO)
piperidine  (ISO)
piperine  (ISO)
poly(I:C)  (ISO)
poly(methyl methacrylate) macromolecule  (ISO)
pomalidomide  (ISO)
prednisolone  (ISO)
proanthocyanidin  (EXP)
progesterone  (ISO)
propanil  (ISO)
prostaglandin E2  (ISO)
pyrazoles  (ISO)
Pyridostigmine bromide  (ISO)
pyrimethamine  (ISO)
pyrrolidine dithiocarbamate  (ISO)
quercetin  (ISO)
reactive oxygen species  (ISO)
resveratrol  (ISO)
Rhein  (ISO)
ribavirin  (ISO)
rimexolone  (ISO)
rottlerin  (ISO)
S-adenosyl-L-methioninate  (ISO)
S-adenosyl-L-methionine  (ISO)
SB 203580  (ISO)
selenium atom  (EXP)
serpentine asbestos  (ISO)
silicon dioxide  (ISO)
simvastatin  (ISO)
sirolimus  (EXP,ISO)
sodium acetate trihydrate  (ISO)
sodium arsenite  (ISO)
sodium bromate  (ISO)
sodium dichromate  (ISO)
sodium dodecyl sulfate  (ISO)
sodium fluoride  (EXP)
sodium hexachloroplatinate  (ISO)
spironolactone  (ISO)
SR 144528  (ISO)
streptozocin  (EXP)
sulfasalazine  (ISO)
sulforaphane  (ISO)
sulfur dioxide  (EXP)
sumatriptan  (EXP)
Sunset Yellow FCF  (ISO)
syringic acid  (ISO)
T-2 toxin  (ISO)
tacrolimus hydrate  (EXP,ISO)
tamoxifen  (ISO)
Terfenadine  (ISO)
tert-butanol  (ISO)
tetrachloromethane  (EXP,ISO)
tetrathiomolybdate(2-)  (ISO)
thalidomide  (EXP,ISO)
theophylline  (ISO)
thioacetamide  (ISO)
titanium dioxide  (ISO)
tofacitinib  (ISO)
toluene  (ISO)
toluene 2,4-diisocyanate  (ISO)
trans-anethole  (ISO)
trans-caffeic acid  (ISO)
trans-isoeugenol  (ISO)
Tributyltin oxide  (EXP,ISO)
tributyrin  (ISO)
trichloroacetic acid  (ISO)
trichloroethene  (ISO)
trichostatin A  (ISO)
triethanolamine  (ISO)
trimellitic anhydride  (ISO)
tropisetron  (EXP)
Tungsten carbide  (ISO)
urethane  (ISO)
ursodeoxycholic acid  (ISO)
verrucarin A  (ISO)
vincristine  (EXP)
vitamin E  (EXP)
warfarin  (ISO)
zearalenone  (ISO)
zidovudine  (ISO)
zinc atom  (EXP,ISO)
zinc sulfate  (ISO)
zinc(0)  (EXP,ISO)
zoledronic acid  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
activated T cell proliferation  (ISO)
adaptive immune response  (IEA)
extrinsic apoptotic signaling pathway in absence of ligand  (ISO)
G protein-coupled receptor signaling pathway  (IMP)
gene expression  (ISO)
leukocyte activation involved in immune response  (ISO)
lymphocyte proliferation  (ISO)
negative regulation of B cell apoptotic process  (ISO)
negative regulation of heart contraction  (IDA)
negative regulation of inflammatory response  (ISO)
negative regulation of lymphocyte proliferation  (ISO)
negative regulation of protein phosphorylation  (IDA)
negative regulation of T-helper 17 cell differentiation  (ISO)
positive regulation of activated T cell proliferation  (ISO)
positive regulation of B cell proliferation  (ISO)
positive regulation of cytosolic calcium ion concentration  (IDA)
positive regulation of dendritic spine development  (IDA)
positive regulation of immunoglobulin production  (ISO)
positive regulation of interleukin-17 production  (ISO)
positive regulation of isotype switching to IgG isotypes  (ISO)
positive regulation of plasma cell differentiation  (ISO)
positive regulation of protein phosphorylation  (IDA)
positive regulation of regulatory T cell differentiation  (IDA)
positive regulation of T cell differentiation  (IDA)
positive regulation of T cell proliferation  (IDA,ISO)
positive regulation of transcription by RNA polymerase II  (ISO)
positive regulation of type II interferon production  (ISO)
positive regulation of tyrosine phosphorylation of STAT protein  (ISO)
protein kinase C-activating G protein-coupled receptor signaling pathway  (IMP)
regulation of CD4-positive, alpha-beta T cell proliferation  (ISO)
regulation of T cell homeostatic proliferation  (ISO)
response to ethanol  (IDA)
signal transduction  (ISO)
T cell proliferation  (ISO)
transcription by RNA polymerase II  (ISO)
tyrosine phosphorylation of STAT protein  (ISO)

Cellular Component

Molecular Function

References

References - curated
# Reference Title Reference Citation
1. Severity of mucosal inflammation as a predictor for alterations of visceral sensory function in a rat model. Adam B, etal., Pain. 2006 Jul;123(1-2):179-86. Epub 2006 Apr 12.
2. Tumour necrosis factor-alpha and interleukin-2 in pus aspirate and blood in patients with amoebic liver abscess. Agarwal SK, etal., J Assoc Physicians India. 1999 Nov;47(11):1065-7.
3. Immunologic studies in patients with Takayasu's arteritis. III. Immunoregulatory changes. Alcocer-Varela J, etal., Clin Exp Rheumatol. 1989 Jul-Aug;7(4):345-50.
4. Immunological predictors of different responses to combination therapy with interferon alpha and ribavirin in patients with chronic hepatitis C. Amaraa R, etal., J Gastroenterol. 2003;38(3):254-9. doi: 10.1007/s005350300044.
5. Cytokine production, activation marker, and skin homing receptor in children with atopic dermatitis and bronchial asthma. Antunez C, etal., Pediatr Allergy Immunol. 2006 May;17(3):166-74.
6. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. Becker JC, etal., J Exp Med. 1996 May 1;183(5):2361-6. doi: 10.1084/jem.183.5.2361.
7. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Becker JC, etal., Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2702-7.
8. Expression of immunoregulatory cytokines during acute and chronic middle ear immune response. Bikhazi P and Ryan AF, Laryngoscope. 1995 Jun;105(6):629-34.
9. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Bui LA, etal., Hum Gene Ther. 1997 Dec 10;8(18):2173-82. doi: 10.1089/hum.1997.8.18-2173.
10. Interleukin 1 (IL-1) and IL-1-receptor antagonist (IL-1-RA) in middle ear cholesteatoma: an analysis of protein production and biological activity. Bujia J, etal., Eur Arch Otorhinolaryngol. 1996;253(4-5):252-5.
11. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states. Butler LD, etal., Cancer Res. 1988 Nov 1;48(21):6081-9.
12. Opioid receptor-mediated effects of interleukin-2 on the [Ca2+]i transient and contraction in isolated ventricular myocytes of the rat. Cao CM, etal., Pflugers Arch 2002 Feb;443(4):635-42.
13. Efficacy of Large Doses of IL-2-Activated Human Leukocyte Antigen Haploidentical Peripheral Blood Stem Cells on Refractory Metastatic Renal Cell Carcinoma. Cao S, etal., Cancer Biother Radiopharm. 2011 Aug;26(4):503-10. Epub 2011 Aug 3.
14. Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats. Case JP, etal., Proc Natl Acad Sci U S A. 1989 Jan;86(1):287-91.
15. Spinal injection of IL-2 or IL-15 alters mechanical and thermal withdrawal thresholds in rats. Cata JP, etal., Neurosci Lett. 2008 May 23;437(1):45-9. doi: 10.1016/j.neulet.2008.03.074. Epub 2008 Mar 29.
16. Mechanism of the impaired T-cell proliferation in adult rats exposed to alcohol in utero. Chang MP, etal., Int J Immunopharmacol. 1994 Apr;16(4):345-57.
17. Comparison of the expression of interferon gamma, IL2, IL4, and lymphotoxin mRNA in experimental autoimmune uveoretinitis. Charteris DG and Lightman SL, Br J Ophthalmol. 1994 Oct;78(10):786-90.
18. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. Chen J, etal., J Virol. 2010 Feb;84(3):1289-301. Epub 2009 Nov 11.
19. Delayed reactions to contrast media after interleukin-2 immunotherapy. Choyke PL, etal., Radiology. 1992 Apr;183(1):111-4.
20. Family based association analysis of the IL2 and IL15 genes in allergic disorders. Christensen U, etal., Eur J Hum Genet. 2006 Feb;14(2):227-35.
21. Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Chuang YC, etal., Neurourol Urodyn. 2011 Mar;30(3):421-7. doi: 10.1002/nau.20981. Epub 2010 Sep 21.
22. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Clary BM, etal., Cancer Gene Ther. 1997 Mar-Apr;4(2):97-104.
23. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil. Clements PJ, etal., J Rheumatol. 1990 Jul;17(7):908-10.
24. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cortesina G, etal., Cancer. 1988 Dec 15;62(12):2482-5.
25. Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients. Dammermann W, etal., J Transl Med. 2015 May 13;13:157. doi: 10.1186/s12967-015-0513-1.
26. Purification and initial characterization of rat interleukin 2. Di Sabato G Proc Natl Acad Sci U S A. 1982 May;79(9):3020-3.
27. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis. Diestelhorst J, etal., Sci Rep. 2018 Jan 11;8(1):419. doi: 10.1038/s41598-017-18818-5.
28. Lack of IL-2 in PPAR-alpha-deficient mice triggers allergic contact dermatitis by affecting regulatory T cells. Dubrac S, etal., Eur J Immunol. 2011 Jul;41(7):1980-91. doi: 10.1002/eji.201041357. Epub 2011 Jun 6.
29. Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis. Farouk S, etal., PLoS One. 2018 Oct 22;13(10):e0206130. doi: 10.1371/journal.pone.0206130. eCollection 2018.
30. Inflammation Profiling of Critically Ill Coronavirus Disease 2019 Patients. Fraser DD, etal., Crit Care Explor. 2020 Jun 22;2(6):e0144. doi: 10.1097/CCE.0000000000000144. eCollection 2020 Jun.
31. Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H/HeJ mice. Freyschmidt-Paul P, etal., J Invest Dermatol. 2005 Nov;125(5):945-51.
32. [Relations between IL-2-330 polymorphisms and the outcome of hepatitis B and/or hepatitis C virus infection]. Gao QJ, etal., Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Sep;31(9):1041-5.
33. Peroxisomal biogenesis disorder biomarkers. Ghoneim W, etal., Clin Lab. 2011;57(7-8):469-80.
34. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection. Golden-Mason L, etal., J Virol. 2007 Sep;81(17):9292-8. doi: 10.1128/JVI.00834-07. Epub 2007 Jun 6.
35. Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery. Graf MR, etal., J Neuroimmunol. 2003 Jul;140(1-2):49-60.
36. IL-2 may possess neuroprotective properties in glaucomatous optic neuropathy. Hautala N, etal., Acta Ophthalmol. 2011 Aug 11. doi: 10.1111/j.1755-3768.2011.02219.x.
37. Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL-2 gene-modified Lewis lung carcinoma cells. Heike Y, etal., Int J Cancer. 1997 Dec 10;73(6):844-9.
38. Mast cell interleukin-2 production contributes to suppression of chronic allergic dermatitis. Hershko AY, etal., Immunity. 2011 Oct 28;35(4):562-71. doi: 10.1016/j.immuni.2011.07.013. Epub 2011 Oct 6.
39. Impaired production of interleukin-2(IL2) in patients with Graves' disease by newly developed IL2 radioimmunoassay. Hirooka Y, etal., Exp Clin Endocrinol. 1990 Sep;96(1):64-72.
40. Regulation of heat-shock protein (hsp70) gene expression by hGH and IL2 in rat Nb2 lymphoma cells. Horn S, etal., Mol Cell Endocrinol. 1994 Nov;105(2):139-46.
41. Interleukin 2 therapy in severe atopic dermatitis. Hsieh KH, etal., J Clin Immunol. 1991 Jan;11(1):22-8.
42. Intrathecal administration of triptolide, a T lymphocyte inhibitor, attenuates chronic constriction injury-induced neuropathic pain in rats. Hu JY, etal., Brain Res. 2012 Feb 3;1436:122-9. doi: 10.1016/j.brainres.2011.11.051. Epub 2011 Dec 4.
43. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Huang C, etal., Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
44. IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease. Huberman M, etal., J Neurol Sci. 1995 Jun;130(2):161-4.
45. Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2. Ishikawa T, etal., Acta Otolaryngol. 1989 May-Jun;107(5-6):346-51.
46. Response of lymphocyte subsets and cytokines to Shenyang prescription in Sprague-Dawley rats with tongue squamous cell carcinomas induced by 4NQO. Jiang C, etal., BMC Cancer. 2007 Mar 5;7:40.
47. IL-2 and IFN-gamma in the retina of diabetic rats. Johnsen-Soriano S, etal., Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):985-90. Epub 2010 Mar 6.
48. Deficiency of interleukin-2 production and interleukin-2 receptor expression on peripheral blood leukocytes after phytohemagglutinin stimulation in pemphigus. Kermani-Arab V, etal., J Invest Dermatol. 1984 Aug;83(2):101-4.
49. Circulatory levels of T-cell cytokines (interleukin -2, IL-4, IL-17, and transforming growth factor-beta) in patients with vitiligo. Khan R, etal., J Am Acad Dermatol. 2012 Mar;66(3):510-1. doi: 10.1016/j.jaad.2011.07.018.
50. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer. Kim SH, etal., Cancer Gene Ther. 2000 Sep;7(9):1279-85.
51. Recombinant interleukin 2 enhances spontaneous insulin-dependent diabetes in BB rats. Kolb H, etal., Eur J Immunol. 1986 Feb;16(2):209-12.
52. Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis. Kondo N, etal., Biotherapy. 1994;8(1):19-22.
53. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Koulmanda M, etal., Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13074-9. Epub 2007 Aug 1.
54. Interleukin-2 affects cochlear function gradually but reversibly. Kubo T, etal., ORL J Otorhinolaryngol Relat Spec. 1998 Sep-Oct;60(5):272-7.
55. Intraocular Interleukin-17 and Proinflammatory Cytokines in HLA-A29-Associated Birdshot Chorioretinopathy. Kuiper JJ, etal., Am J Ophthalmol. 2011 Aug;152(2):177-182.e1. Epub 2011 May 13.
56. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Lacomba MS, etal., Arch Ophthalmol. 2000 Jun;118(6):768-72.
57. T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production. Lai KN, etal., Acta Endocrinol (Copenh). 1989 May;120(5):602-9.
58. Interleukin 2 suppression of a murine bladder cancer implanted into kidney, bladder and skin; its organ specificity. Lee KE, etal., J Urol. 1988 Oct;140(4):840-3.
59. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Li D, etal., Clin Cancer Res. 1999 Jun;5(6):1551-6.
60. IL-2 and IL-4 stimulate MEK1 expression and contribute to T cell resistance against suppression by TGF-beta and IL-10 in asthma. Liang Q, etal., J Immunol. 2010 Nov 15;185(10):5704-13. Epub 2010 Oct 6.
61. Antiviral role of toll-like receptors and cytokines against the new 2009 H1N1 virus infection. Liu Y, etal., Mol Biol Rep. 2011 May 21.
62. Suppression of complete Freund's adjuvant-induced adjuvant arthritis by cobratoxin. Liu YL, etal., Acta Pharmacol Sin. 2009 Feb;30(2):219-27. doi: 10.1038/aps.2008.20. Epub 2009 Jan 26.
63. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. Lode HN, etal., J Natl Cancer Inst. 1997 Nov 5;89(21):1586-94. doi: 10.1093/jnci/89.21.1586.
64. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Massumoto C, etal., Bone Marrow Transplant. 1996 Mar;17(3):351-6.
65. Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. Mattuzzi S, etal., J Rheumatol. 2007 May;34(5):997-1004. Epub 2007 Apr 15.
66. Sequence of rat interleukin 2 and anomalous binding of a mouse interleukin 2 cDNA probe to rat MHC class II-associated invariant chain mRNA. McKnight AJ, etal., Immunogenetics 1989;30(2):145-7.
67. Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis. Mele D, etal., Clin Immunol. 2018 Mar;188:31-37. doi: 10.1016/j.clim.2017.12.004. Epub 2017 Dec 9.
68. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
69. In vivo effect of surfactant on inflammatory cytokines during endotoxin-induced lung injury in rodents. Mittal N and Sanyal SN, J Immunotoxicol. 2011 Oct-Dec;8(4):274-83. Epub 2011 Jul 18.
70. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Miyasaka N, etal., Clin Immunol Immunopathol. 1984 Apr;31(1):109-17.
71. Increased expression of HBZ and Foxp3 mRNA in bronchoalveolar lavage cells taken from human T-lymphotropic virus type 1-associated lung disorder patients. Nakayama Y, etal., Intern Med. 2013;52(23):2599-609. doi: 10.2169/internalmedicine.52.0845.
72. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
73. The biochemical study of rat T-cell growth factor (interleukin 2). Nesmeyanov VA, etal., Immunol Lett. 1984;7(5):273-7.
74. In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2. Neville ME, etal., Cytokine. 2001 Dec 21;16(6):239-50.
75. Structural basis for binding multiple ligands by the common cytokine receptor gamma-chain. Olosz F and Malek TR, J Biol Chem 2002 Apr 5;277(14):12047-52.
76. Impact of endothelial activation on infective and inflammatory complications after cardiac surgery in type II diabetes mellitus. Onorati F, etal., Int J Artif Organs. 2011 Jun;34(6):469-80. doi: 10.5301/IJAO.2011.8329.
77. Decreased in vitro lymphocyte stimulation and reduced sensitivity to IL-2 in patients with alopecia areata. Orecchia G, etal., Arch Dermatol Res. 1988;280 Suppl:S47-50.
78. Prolongation of cardiac allograft survival in rats by treatment with anti-interleukin 2 antiserum. Osaki T, etal., Acta Med Okayama. 1988 Apr;42(2):77-8.
79. Defective interferon-gamma production in ataxia-telangiectasia. Paganelli R, etal., Clin Immunol Immunopathol. 1984 Sep;32(3):387-91.
80. Anti-CD25 mAb, anti-IL2 mAb, and IL2 block tolerance induction through anti-CD154 mAb and rapamycin in xenogeneic islet transplantation. Pan H, etal., Transplant Proc. 2007 Dec;39(10):3452-4.
81. Binding of interleukin 2 to gangliosides. Parker J, etal., FEBS Lett. 1984 May 21;170(2):391-5.
82. Reduced production of hyperalgesic substances by mononuclear cells from aged rats incubated with carrageenan: role of interleukin 2 and prostaglandins. Pereira LS, etal., Inflamm Res. 2003 Mar;52(3):119-25.
83. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
84. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
85. Novel 1,4-benzothazines obliterate COX-2 mediated JAK-2/STAT-3 signals with potential regulation of oxidative and metabolic stress during colorectal cancer. Rai A, etal., Pharmacol Res. 2018 Jun;132:188-203. doi: 10.1016/j.phrs.2017.12.010. Epub 2017 Dec 8.
86. Release of IL-1 and IL-2 and expression of IL-2 receptors as a function of postnatal age and sex. Ramseier H, etal., Eur Cytokine Netw. 1993 Nov-Dec;4(6):453-9.
87. Interleukin 2 and a lactogen regulate proliferation and protein phosphorylation in Nb2 cells. Rayhel EJ, etal., Biochem J. 1988 Jan 15;249(2):333-8.
88. Interleukin 2 deficiency in murine Leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. Reiner NE and Finke JH, J Immunol. 1983 Sep;131(3):1487-91.
89. GOA pipeline RGD automated data pipeline
90. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
91. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
92. Interleukin-2 serum levels variations in recent onset atrial fibrillation are related with cardioversion outcome. Rizos I, etal., Cytokine. 2007 Dec;40(3):157-64. Epub 2007 Oct 17.
93. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. Rizzo LV, etal., J Clin Invest. 1994 Oct;94(4):1668-72.
94. IL1RN VNTR and IL2-330 polymorphic genes are independently associated with chronic immune thrombocytopenia. Rocha AM, etal., Br J Haematol. 2010 Sep;150(6):679-84. doi: 10.1111/j.1365-2141.2010.08318.x.
95. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment. Roh MI, etal., Retina. 2009 Apr;29(4):523-9. doi: 10.1097/IAE.0b013e318195cb15.
96. Vaccination leads to an aberrant FOXP3 T-cell response in non-remitting juvenile idiopathic arthritis. Ronaghy A, etal., Ann Rheum Dis. 2011 Aug 22.
97. Translocation of CD28 to lipid rafts and costimulation of IL-2. Sadra A, etal., Proc Natl Acad Sci U S A 2004 Aug 3;101(31):11422-7. Epub 2004 Jul 27.
98. Interleukin (IL)-12, IL-2, and IL-6 gene polymorphisms in Takayasu's arteritis from Turkey. Saruhan-Direskeneli G, etal., Hum Immunol. 2006 Sep;67(9):735-40. Epub 2006 Jul 20.
99. Interleukin-2 receptor expression and interleukin-2 production in bullous pemphigoid. Schaller J, etal., Arch Dermatol Res. 1990;282(4):223-6.
100. Correlation of measurable serum markers of inflammation with lung levels following bilateral femur fracture in a rat model. Sears BW, etal., J Inflamm Res. 2010 Aug 1;2010(3):105-114.
101. Involvement of NK1.1+ {gamma}{delta}T Cells in the IL-18 Plus IL-2-Induced Interstitial Lung Disease. Segawa S, etal., Am J Respir Cell Mol Biol. 2011 Jan 21.
102. [Interleukin-2 and interleukin-4 blood levels in sinusitis]. Selezn'ov KH, etal., Fiziol Zh. 2001;47(5):69-73.
103. Local inflammatory markers and systemic endotoxin in aggressive periodontitis. Shaddox LM, etal., J Dent Res. 2011 Sep;90(9):1140-4. Epub 2011 Jul 5.
104. Association of interleukin-2, interleukin-4 and transforming growth factor-beta gene polymorphisms with Behcet's disease. Shahram F, etal., Clin Exp Rheumatol. 2011 May 31.
105. Interleukin-2 enhances dendritic development and spinogenesis in cultured hippocampal neurons. Shen Y, etal., Anat Rec (Hoboken). 2010 Jun;293(6):1017-23.
106. Mechanistic investigation of immunosuppression in patients with condyloma acuminata. Shi YJ, etal., Mol Med Rep. 2013 Aug;8(2):480-6. doi: 10.3892/mmr.2013.1511. Epub 2013 Jun 6.
107. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Shin HJ, etal., Blood. 2011 Aug 25;118(8):2342-2350. Epub 2011 Jul 6.
108. Production of interleukin-2 and interleukin-2 inhibitor in patients with palmoplantar pustulosis. Shiohara T, etal., Acta Derm Venereol. 1987;67(5):422-6.
109. Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder. Smith AK, etal., Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156(6):700-8. doi: 10.1002/ajmg.b.31212. Epub 2011 Jun 28.
110. Enhanced cytotoxic response of natural killer cells to interleukin-2 in Alzheimer's disease. Solerte SB, etal., Dementia. 1996 Nov-Dec;7(6):343-8.
111. Adeno-associated viral-mediated gene transfer to hepatoma: thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated than in GCV-treated animals. Su H, etal., Mol Ther. 2000 Jun;1(6):509-15.
112. [Effect of diethyldithiocarbamate on interleukin 2 production of patients with oral lichen planus and its clinical therapeutic efficacy]. Su M, etal., Zhongguo Yao Li Xue Bao. 1991 Jul;12(4):378-80.
113. Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis. Taylor AE, etal., Hepatology. 2018 Nov;68(5):1905-1921. doi: 10.1002/hep.30061. Epub 2018 Sep 30.
114. Induction of suppressor T cells by interleukin 2. Ting CC, etal., J Immunol. 1984 Jul;133(1):261-6.
115. Music exposure induced prolongation of cardiac allograft survival and generated regulatory CD4(+) cells in mice. Uchiyama M, etal., Transplant Proc. 2012 May;44(4):1076-9. doi: 10.1016/j.transproceed.2012.02.008.
116. Human knee synovial fluid cytokines correlated with grade of knee osteoarthritis--a pilot study. Vangsness CT Jr, etal., Bull NYU Hosp Jt Dis. 2011;69(2):122-7.
117. Role of IL-2 in rat fetal thymocyte development. Varas A, etal., Int Immunol. 1997 Oct;9(10):1589-99.
118. The SaeR/S gene regulatory system induces a pro-inflammatory cytokine response during Staphylococcus aureus infection. Watkins RL, etal., PLoS One. 2011;6(5):e19939. Epub 2011 May 13.
119. [Correlation of polymorphisms of interleukin-2 gene and HBV DNA copies in patients with chronic hepatitis B]. Wei YS, etal., Zhonghua Gan Zang Bing Za Zhi. 2008 Dec;16(12):889-92.
120. Severe combined immunodeficiency due to a specific defect in the production of interleukin-2. Weinberg K and Parkman R, N Engl J Med. 1990 Jun 14;322(24):1718-23.
121. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Xiang R, etal., Cancer Res. 1997 Nov 1;57(21):4948-55.
122. Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia. Xie WR, etal., Neuroscience. 2006 Oct 27;142(3):809-22. Epub 2006 Aug 2.
123. [Molecular biological study of aloe vera in the treatment of experimental allergic rhinitis in rat]. Yu H, etal., Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2002 May;16(5):229-31.
124. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Zager JS, etal., Mol Med. 2001 Aug;7(8):561-8.
125. [The clinical studies of 30 cases perennial allergic rhinitis with special immunotherapy]. Zhang H and Hua Q, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2007 Apr;21(8):356-8.
126. Study on the T-helper cell 1/2 cytokine profile in blister fluid of patients with herpes zoster and its clinical significance. Zhang M, etal., J Dermatol. 2011 Dec;38(12):1158-62. doi: 10.1111/j.1346-8138.2011.01289.x. Epub 2011 Sep 29.
127. Hyperglycemic Ins2AkitaLdlr-/- mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease. Zhou C, etal., J Lipid Res. 2011 Aug;52(8):1483-93. Epub 2011 May 23.
Additional References at PubMed
PMID:1588041   PMID:1830926   PMID:7584142   PMID:7589135   PMID:7688139   PMID:8262055   PMID:8402910   PMID:8612131   PMID:9184696   PMID:9492004   PMID:10072077   PMID:10485657  
PMID:11728336   PMID:11948286   PMID:12082633   PMID:12874832   PMID:12878449   PMID:15087456   PMID:15950774   PMID:16204630   PMID:16227984   PMID:16482511   PMID:16769892   PMID:17152351  
PMID:17213291   PMID:17433709   PMID:18264770   PMID:18343154   PMID:18407603   PMID:18471351   PMID:18628674   PMID:18827184   PMID:19088061   PMID:19139201   PMID:19589546   PMID:21262542  
PMID:21668966   PMID:21726905   PMID:22201020   PMID:22659252   PMID:22968459   PMID:23262141   PMID:23395675   PMID:24853588   PMID:25642768   PMID:26927369   PMID:28092075   PMID:28396406  


Genomics

Candidate Gene Status
Il2 is a candidate Gene for QTL Eau5
Il2 is a candidate Gene for QTL Iddm32
Comparative Map Data
Il2
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
mRatBN7.22120,004,862 - 120,009,566 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl2120,004,862 - 120,009,566 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx2126,574,220 - 126,578,924 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.02124,686,729 - 124,691,433 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.02119,315,685 - 119,320,389 (-)NCBIRnor_WKY
Rnor_6.02123,847,150 - 123,851,854 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl2123,847,150 - 123,851,854 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.02143,460,866 - 143,465,570 (-)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.42123,655,005 - 123,659,709 (-)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.12123,599,966 - 123,604,671 (-)NCBI
Celera2114,959,889 - 114,964,593 (-)NCBICelera
Cytogenetic Map2q25NCBI
IL2
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh384122,451,470 - 122,456,725 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl4122,451,470 - 122,456,725 (-)EnsemblGRCh38hg38GRCh38
GRCh374123,372,625 - 123,377,880 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 364123,592,075 - 123,597,100 (-)NCBINCBI36Build 36hg18NCBI36
Build 344123,730,232 - 123,735,485NCBI
Celera4120,756,030 - 120,761,055 (-)NCBICelera
Cytogenetic Map4q27NCBI
HuRef4119,099,231 - 119,104,256 (-)NCBIHuRef
CHM1_14123,349,113 - 123,354,138 (-)NCBICHM1_1
T2T-CHM13v2.04125,755,609 - 125,760,864 (-)NCBIT2T-CHM13v2.0
Il2
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm39337,174,862 - 37,180,103 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl337,174,672 - 37,180,108 (-)EnsemblGRCm39 Ensembl
GRCm38337,120,713 - 37,125,954 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl337,120,523 - 37,125,959 (-)EnsemblGRCm38mm10GRCm38
MGSCv37337,019,635 - 37,024,876 (-)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36337,312,271 - 37,317,502 (-)NCBIMGSCv36mm8
Celera337,007,247 - 37,012,480 (-)NCBICelera
Cytogenetic Map3BNCBI
cM Map318.3NCBI
Il2
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_00495542818,162,467 - 18,168,265 (+)EnsemblChiLan1.0
ChiLan1.0NW_00495542818,163,010 - 18,168,157 (+)NCBIChiLan1.0ChiLan1.0
IL2
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
PanPan1.14125,782,563 - 125,787,819 (-)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl4125,782,563 - 125,787,984 (-)Ensemblpanpan1.1panPan2
Mhudiblu_PPA_v04114,637,328 - 114,642,586 (-)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
IL2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11917,750,780 - 17,756,394 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1917,750,780 - 17,756,394 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1917,968,837 - 17,974,439 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01917,869,103 - 17,874,712 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1917,869,103 - 17,874,712 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11917,821,680 - 17,827,284 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01918,101,949 - 18,107,555 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01918,572,248 - 18,577,858 (+)NCBIUU_Cfam_GSD_1.0
Il2
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440530165,520,154 - 65,524,908 (+)NCBIHiC_Itri_2
SpeTri2.0NW_0049366621,594,953 - 1,599,625 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
IL2
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl8101,640,944 - 101,645,609 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.18101,640,938 - 101,645,683 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.28108,797,437 - 108,802,149 (+)NCBISscrofa10.2Sscrofa10.2susScr3
IL2
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.1769,729,635 - 69,736,279 (-)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl769,730,282 - 69,734,969 (-)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366603748,691,838 - 48,697,094 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Il2
(Heterocephalus glaber - naked mole-rat)
Naked Mole-rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_0046247772,885,535 - 2,890,453 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046247772,885,537 - 2,890,453 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2

Position Markers
UniSTS:143556  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.22120,009,437 - 120,009,507 (+)MAPPERmRatBN7.2
Rnor_6.02123,851,726 - 123,851,795NCBIRnor6.0
Rnor_5.02143,465,442 - 143,465,511UniSTSRnor5.0
RGSC_v3.42123,659,581 - 123,659,650UniSTSRGSC3.4
Celera2114,964,465 - 114,964,534UniSTS
Cytogenetic Map2q25UniSTS


QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1302794Stl27Serum triglyceride level QTL 274.40.0001blood triglyceride amount (VT:0002644)plasma triglyceride level (CMO:0000548)225413423143657569Rat
1358894Kidm24Kidney mass QTL 244.03kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)225413423157142209Rat
1358899Kidm23Kidney mass QTL 233.88kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)225413423157142209Rat
1358901Cm38Cardiac mass QTL 382heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)225413423157142209Rat
1358904Cm39Cardiac mass QTL 392.26heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)225413423157142209Rat
1358910Kidm27Kidney mass QTL 275.77kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)225413423157142209Rat
1358911Kidm28Kidney mass QTL 285.42kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)225413423157142209Rat
1358913Cm41Cardiac mass QTL 412.73heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)225413423203928301Rat
1358917Cm42Cardiac mass QTL 422.82heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)225413423203928301Rat
1358887Bw50Body weight QTL 502.39body mass (VT:0001259)body weight (CMO:0000012)225413652157142078Rat
1358908Bw49Body weight QTL 493.36body mass (VT:0001259)body weight (CMO:0000012)225413652157142078Rat
1354603Bp243Blood pressure QTL 2433.9arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)226917817127469484Rat
2290453Scl55Serum cholesterol level QTL 552.83blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)226917817136917119Rat
2293835Kiddil5Kidney dilation QTL 53.8kidney pelvis morphology trait (VT:0004194)hydronephrosis severity score (CMO:0001208)242804607157142209Rat
2293843Kiddil6Kidney dilation QTL 63.1kidney pelvis morphology trait (VT:0004194)hydronephrosis severity score (CMO:0001208)242804607182042367Rat
1298074Bp164Blood pressure QTL 1640.003arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)242804607202447032Rat
1298085Bp165Blood pressure QTL 1650.0006arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)242804607202447032Rat
61467Bp14Blood pressure QTL 142.2arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)243154682202446871Rat
61467Bp14Blood pressure QTL 142.2arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)243154682202446871Rat
2293671Bss44Bone structure and strength QTL 4410.970.0001lumbar vertebra morphology trait (VT:0010494)lumbar vertebra cortical cross-sectional area (CMO:0001690)243162366148478373Rat
1354601Slep1Serum leptin concentration QTL 15.39blood leptin amount (VT:0005667)serum leptin level (CMO:0000780)243171017184114403Rat
631266Bp132Blood pressure QTL 1320.0005arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)246123260202447032Rat
1331760Bp206Blood pressure QTL 2063.62454arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)256043031202447032Rat
1558648Smcn1Smooth muscle cell number QTL 10.039blood vessel smooth muscle cell quantity (VT:0010525)aorta smooth muscle cell count per unit vessel length (CMO:0001646)259134147127460910Rat
61438Cia7Collagen induced arthritis QTL 74.60.0001joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)259324377141596857Rat
1298080Bp163Blood pressure QTL 1630.02arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)266118275202447032Rat
1354648Bp239Blood pressure QTL 2390.001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)266118463226797303Rat
1558653Prcr1Prostate cancer resistance QTL 15prostate integrity trait (VT:0010571)area of ventral prostate occupied by tumorous lesions to total ventral prostate area ratio (CMO:0000899)272532993157142209Rat
1354605Rf48Renal function QTL 482.9blood creatinine amount (VT:0005328)plasma creatinine level (CMO:0000537)274786664206665859Rat
631198Cm22Cardiac mass QTL 224.30.0008heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)276539322150540526Rat
61374Edpm2Estrogen-dependent pituitary mass QTL 24.420.86pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)276539322202447032Rat
2299162Iddm32Insulin dependent diabetes mellitus QTL 322.36blood glucose amount (VT:0000188)age at onset/diagnosis of type 1 diabetes mellitus (CMO:0001140)278665616143657569Rat
1581569Uae32Urinary albumin excretion QTL 320.0001urine protein amount (VT:0005160)urine albumin excretion rate (CMO:0000757)278665619219826953Rat
724534Uae6Urinary albumin excretion QTL 610urine albumin amount (VT:0002871)urine albumin level (CMO:0000130)278665619249053267Rat
61392Bp6Blood pressure QTL 67arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)280270434125270434Rat
1598865Bp296Blood pressure QTL 2962.1arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)281018907126018907Rat
8662832Vetf7Vascular elastic tissue fragility QTL 73.5aorta elastin amount (VT:0003905)aorta wall extracellular elastin dry weight to aorta wall dry weight ratio (CMO:0002002)281689826221035911Rat
1354622Kidm16Kidney mass QTL 163kidney mass (VT:0002707)left kidney wet weight (CMO:0000083)281754530222436696Rat
1354649Kidm17Kidney mass QTL 172.9kidney mass (VT:0002707)calculated kidney weight (CMO:0000160)281754530227146641Rat
1578772Stresp14Stress response QTL 1450.001blood renin amount (VT:0003349)plasma renin activity level (CMO:0000116)282345893130923501Rat
7207808Bmd89Bone mineral density QTL 894.1femur strength trait (VT:0010010)femoral neck ultimate force (CMO:0001703)288862519133862519Rat
2300165Bmd49Bone mineral density QTL 494.80.0001lumbar vertebra mineral mass (VT:0010511)bone mineral density (CMO:0001226)288862519133862519Rat
2300170Bmd45Bone mineral density QTL 4512.10.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)288862519133862519Rat
2300185Bmd46Bone mineral density QTL 468.40.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)288862519133862519Rat
1598862Glom9Glomerulus QTL 93.5kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)292337601137337601Rat
1598863Cm65Cardiac mass QTL 652.3heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)292337601137337601Rat
631566Bp90Blood pressure QTL 900.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)2102803808147803808Rat
8662836Vetf8Vascular elastic tissue fragility QTL 80.66thoracic aorta molecular composition trait (VT:0010568)aorta wall extracellular elastin dry weight to aorta wall extracellular collagen weight ratio (CMO:0002003)2104559726149559726Rat
1581552Pur12Proteinuria QTL 125.190.0009total urine protein amount (VT:0000032)urine protein excretion rate (CMO:0000759)2112103657148076632Rat
631507Bp105Blood pressure QTL 1050.001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)2112456140212696837Rat
634308Sach6Saccharin preference QTL 64.9taste sensitivity trait (VT:0001986)saccharin intake volume to total fluid intake volume ratio (CMO:0001601)2112456140212696837Rat
1354594Despr10Despair related QTL 100.00000249locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)2114654253159654253Rat
1359035Bp276Blood pressure QTL 276arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)2114837527143657569Rat
1359035Bp276Blood pressure QTL 276arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)2114837527143657569Rat
1359030Bp277Blood pressure QTL 277arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)2114837527185876470Rat
1359030Bp277Blood pressure QTL 277arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)2114837527185876470Rat
1578648Bss11Bone structure and strength QTL 114.7femur morphology trait (VT:0000559)femoral neck cortical cross-sectional area (CMO:0001702)2114837527211674221Rat
1554319Bmd2Bone mineral density QTL 213.40.0001lumbar vertebra area (VT:0010570)lumbar vertebra cross-sectional area (CMO:0001689)2114837675212549332Rat
5135226Leukc2Leukocyte quantity QTL 2eosinophil quantity (VT:0002602)blood eosinophil count (CMO:0000033)2118111229149559726Rat
1582257Gluco21Glucose level QTL 213.10.0035blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)2118111229157142209Rat
738007Anxrr7Anxiety related response QTL 74.4exploratory behavior trait (VT:0010471)number of entries into a discrete space in an experimental apparatus (CMO:0000960)2118189491163189491Rat

miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:44
Count of miRNA genes:37
Interacting mature miRNAs:44
Transcripts:ENSRNOT00000023327
Prediction methods:Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


Expression


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
High
Medium
Low 1 1 2 2 5
Below cutoff 1 3 12 3 13 3 1 2 5 2 5 8 1

Sequence


Reference Sequences
RefSeq Acc Id: ENSRNOT00000023327   ⟹   ENSRNOP00000023327
RefSeq Status:
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl2120,004,862 - 120,009,566 (-)Ensembl
Rnor_6.0 Ensembl2123,847,150 - 123,851,854 (-)Ensembl
RefSeq Acc Id: NM_053836   ⟹   NP_446288
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
mRatBN7.22120,004,862 - 120,009,566 (-)NCBI
Rnor_6.02123,847,150 - 123,851,854 (-)NCBI
Rnor_5.02143,460,866 - 143,465,570 (-)NCBI
RGSC_v3.42123,655,005 - 123,659,709 (-)RGD
Celera2114,959,889 - 114,964,593 (-)RGD
Sequence:
Protein Sequences
Protein RefSeqs NP_446288 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAA41427 (Get FASTA)   NCBI Sequence Viewer  
  EDM01295 (Get FASTA)   NCBI Sequence Viewer  
  P17108 (Get FASTA)   NCBI Sequence Viewer  
Reference Sequences
RefSeq Acc Id: NP_446288   ⟸   NM_053836
- Peptide Label: precursor
- UniProtKB: P17108 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: ENSRNOP00000023327   ⟸   ENSRNOT00000023327

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P17108-F1-model_v2 AlphaFold P17108 1-155 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen


Strain Variation

Strain Sequence Variants (mRatBN7.2)
ACI/EurMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
ACI/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN-Lx/CubMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/NHsdMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/NHsdMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BN/SsN (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BUF/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BXH2/CubMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
BXH3/CubMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
DA/OlaHsd (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Envigo
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/DuCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
F344/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FHH/EurMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FXLE16/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
FXLE18/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
GK/FarMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB10/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB2/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB20/IpcvMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB31/IpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
HXB4/IpcvMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LE/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEW/Crl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF10A/StmMcwi (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF11/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF1A/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF1C/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF2B/Stm (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF3/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LEXF4/Stm (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LH/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LL/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
LN/MavRrrcAek (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Kwitek
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
M520/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
M520/NRrrcMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
MR/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
MWF/Hsd (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
PVG/Seac (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Japan
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SHR/OlalpcvMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SHRSP/A3NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SR/JrHsd (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Envigo
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
SS/JrHsdMcwi (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: MCW
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WAG/RijCrl (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WKY/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WKY/NCrl (2019)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: Charles River
Description: Dr. Mindy Dwinell - Hybrid rat diversity program
WN/N (2020)
Visual CSV TAB Printer
Platform: GSPMC-Illumina-NovaSeq6000
Secondary Analysis: BWA_mem_v.0.7.17,_GATK_v.4.1.3.0
Breeder: NIH
Description: Dr. Mindy Dwinell - Hybrid rat diversity program

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:620047 AgrOrtholog
BioCyc Gene G2FUF-53309 BioCyc
Ensembl Genes ENSRNOG00000017348 Ensembl, ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Protein ENSRNOP00000023327 ENTREZGENE, UniProtKB/Swiss-Prot
Ensembl Transcript ENSRNOT00000023327 ENTREZGENE, UniProtKB/Swiss-Prot
Gene3D-CATH 1.20.1250.10 UniProtKB/Swiss-Prot
InterPro 4_helix_cytokine-like_core UniProtKB/Swiss-Prot
  IL-2 UniProtKB/Swiss-Prot
  IL-2_CS UniProtKB/Swiss-Prot
KEGG Report rno:116562 UniProtKB/Swiss-Prot
NCBI Gene 116562 ENTREZGENE
Pfam IL2 UniProtKB/Swiss-Prot
PhenoGen Il2 PhenoGen
PRINTS INTERLEUKIN2 UniProtKB/Swiss-Prot
PROSITE INTERLEUKIN_2 UniProtKB/Swiss-Prot
SMART IL2 UniProtKB/Swiss-Prot
Superfamily-SCOP SSF47266 UniProtKB/Swiss-Prot
UniProt IL2_RAT UniProtKB/Swiss-Prot, ENTREZGENE


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2004-09-10 Il2  interleukin 2      Symbol and Name status set to approved 1299863 APPROVED
2002-08-07 Il2  interleukin 2      Symbol and Name status set to provisional 70820 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_process involved in contraction in vetricular myocytes 727354
gene_regulation mRNA level dramatically increases after cyclophosphamide (CYP)-induced cystitis 625630